MWM
BMRN icon

MBE Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

MBE Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-113
Closed -$9K – 100
2020
Q1 		$9K Buy
+113
New +$9.74K 0.01% 292

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

MBE Wealth Management's BMRN Position: Q2 2020 in Review

MBE Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 113 shares — an estimated $9K sold.

MBE Wealth Management first reported a position in BMRN in Q1 2020 and held it in 1 quarter. The position peaked at $9K in Q1 2020. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

  • MBE Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • MBE Wealth Management sold 113 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $9K.
  • MBE Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • MBE Wealth Management's BioMarin Pharmaceuticals position peaked at $9K in Q1 2020.
  • 527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on MBE Wealth Management's 13F filing for Q2 2020, filed 14 Aug 2020.